Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771930 | 0.90 | SMN1; SMN2 (0.42) | THRBTP53SMN1; SMN2LMNAPDE10A | |
| SCHEMBL5247389 | 0.87 | ALDH1A1 (0.46) | ALDH1A1TP53SMN1; SMN2LMNAGAA | |
| SCHEMBL4779000 | 0.87 | ALDH1A1 (0.41) | THRBALDH1A1SMN1; SMN2LMNAGAA | |
| SCHEMBL4772378 | 0.86 | ROCK1 (0.46) | SMN1; SMN2PDE10APDGFRBEGFRCSF1R | |
| SCHEMBL4778505 | 0.86 | EGFR (0.38) | THRBSMN1; SMN2PDE10APDGFRBEGFR | |
| SCHEMBL4772005 | 0.85 | ALDH1A1 (0.46) | THRBALDH1A1LMNAGAA | |
| SCHEMBL4792971 | 0.85 | ALDH1A1 (0.46) | ALDH1A1TP53SMN1; SMN2LMNA | |
| SCHEMBL4792968 | 0.85 | ALDH1A1 (0.46) | ALDH1A1TP53SMN1; SMN2LMNA | |
| SCHEMBL4772434 | 0.85 | ALDH1A1 (0.46) | THRBALDH1A1SMN1; SMN2LMNAGAA | |
| SCHEMBL4778732 | 0.84 | ALDH1A1 (0.48) | ALDH1A1TP53SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1991530-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-19 | — | — | EP | claimed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | claimed |
| WO-2007098169-A1 | CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-08-30 | — | — | WO | claimed |
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265256-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | THRB 2802/4885ALDH1A1 365/4885TP53 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.